Overview

Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours

Status:
Recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
A study to find out whether olaparib is safe and well tolerated when administered to children and adolescents with solid tumours
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Olaparib